Cao, Changcheng 曹長城

Censure of Fusen Pharma (1652) and 5 directors
SEHK, 4-Jan-2023
The firm was listed in mid-2018 after raising HK$397m. It spent most of 2019 siphoning off RMB258m in unapproved "advances" to a company half-owned by Cao Changcheng, the founder, Chairman and controlling shareholder of Fusen Pharma. The funds were (apparently) repaid by Christmas Day that year.
Fusen Pharma (1652): unapproved advances to company 50% owned by Chairman and controlling shareholder
Company announcement, 23-Mar-2020

Sign up for our free newsletter

Recommend Webb-site to a friend

Copyright & disclaimer, Privacy policy

Back to top